AU2016307969C1 - Antibacterial agents comprising a pyrazino[2,3-b][1,4]oxazin-3-one or a related ring system - Google Patents
Antibacterial agents comprising a pyrazino[2,3-b][1,4]oxazin-3-one or a related ring system Download PDFInfo
- Publication number
- AU2016307969C1 AU2016307969C1 AU2016307969A AU2016307969A AU2016307969C1 AU 2016307969 C1 AU2016307969 C1 AU 2016307969C1 AU 2016307969 A AU2016307969 A AU 2016307969A AU 2016307969 A AU2016307969 A AU 2016307969A AU 2016307969 C1 AU2016307969 C1 AU 2016307969C1
- Authority
- AU
- Australia
- Prior art keywords
- methyl
- amino
- pyrazino
- compound
- fluoro
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- 0 C*1(C)C(C(**)=C(*)**2)=C2*=**1 Chemical compound C*1(C)C(C(**)=C(*)**2)=C2*=**1 0.000 description 3
- AETOSEGDBPUISS-UHFFFAOYSA-N C=Cc(nc1N2)cnc1OCC2=O Chemical compound C=Cc(nc1N2)cnc1OCC2=O AETOSEGDBPUISS-UHFFFAOYSA-N 0.000 description 1
- YKDJJXDRAVFEBJ-AWEZNQCLSA-N CC(C)(C)OC(NC[C@H]1CN(CCN2c(nc(cc3)OC)c3N=CC2=O)CC1)=O Chemical compound CC(C)(C)OC(NC[C@H]1CN(CCN2c(nc(cc3)OC)c3N=CC2=O)CC1)=O YKDJJXDRAVFEBJ-AWEZNQCLSA-N 0.000 description 1
- VMLVROAZOLUKIS-YLQAJVPDSA-N CC(C)(C)OC(N[C@@H](CC[C@@H]1NCc(c2nc(OC)cnc2cc2)c2F)C[C@H]1O)=O Chemical compound CC(C)(C)OC(N[C@@H](CC[C@@H]1NCc(c2nc(OC)cnc2cc2)c2F)C[C@H]1O)=O VMLVROAZOLUKIS-YLQAJVPDSA-N 0.000 description 1
- ZZDDFYQGRQTLBG-UHFFFAOYSA-N CCOC(C(C(OCC)=O)=CNc(c(F)c1)cc(Br)c1F)=O Chemical compound CCOC(C(C(OCC)=O)=CNc(c(F)c1)cc(Br)c1F)=O ZZDDFYQGRQTLBG-UHFFFAOYSA-N 0.000 description 1
- MSZMNCVNHGPEKB-UHFFFAOYSA-N CCOC(C(C(c1c(c(F)c2)Br)=O)=CNc1c2F)=O Chemical compound CCOC(C(C(c1c(c(F)c2)Br)=O)=CNc1c2F)=O MSZMNCVNHGPEKB-UHFFFAOYSA-N 0.000 description 1
- ILTHSAAOEREORW-UHFFFAOYSA-N CN1c(nc(cc2)OC)c2N=CC1=O Chemical compound CN1c(nc(cc2)OC)c2N=CC1=O ILTHSAAOEREORW-UHFFFAOYSA-N 0.000 description 1
- NSWVYPKCELOMKY-UHFFFAOYSA-N CN1c2nc(OC)ccc2C=CC1=O Chemical compound CN1c2nc(OC)ccc2C=CC1=O NSWVYPKCELOMKY-UHFFFAOYSA-N 0.000 description 1
- OOACEHZOTHYGGY-UHFFFAOYSA-N CN1c2nc(OC)cnc2C=CC1=O Chemical compound CN1c2nc(OC)cnc2C=CC1=O OOACEHZOTHYGGY-UHFFFAOYSA-N 0.000 description 1
- GSBXKPFJTLPTSV-UHFFFAOYSA-N CNc(c(nc(cc1)OC)c1c(F)c1)c1F Chemical compound CNc(c(nc(cc1)OC)c1c(F)c1)c1F GSBXKPFJTLPTSV-UHFFFAOYSA-N 0.000 description 1
- NVVNGHZDVMJDDH-UHFFFAOYSA-N CNc1nccc(cc2)c1nc2OC Chemical compound CNc1nccc(cc2)c1nc2OC NVVNGHZDVMJDDH-UHFFFAOYSA-N 0.000 description 1
- UZXXYQWIOOQURO-UHFFFAOYSA-N COC(c(nc(c(OC1)n2)NC1=O)c2Br)=O Chemical compound COC(c(nc(c(OC1)n2)NC1=O)c2Br)=O UZXXYQWIOOQURO-UHFFFAOYSA-N 0.000 description 1
- RKLLFGBBKXZCAB-UHFFFAOYSA-N COc(cc1F)cc2c1nccc2I Chemical compound COc(cc1F)cc2c1nccc2I RKLLFGBBKXZCAB-UHFFFAOYSA-N 0.000 description 1
- JAMSVDVSKVCYEJ-UHFFFAOYSA-N COc(ccc1c(cc2F)F)nc1c2I Chemical compound COc(ccc1c(cc2F)F)nc1c2I JAMSVDVSKVCYEJ-UHFFFAOYSA-N 0.000 description 1
- NVLXYZOTINRMRQ-UHFFFAOYSA-N COc(ccc1ncc2)cc1c2I Chemical compound COc(ccc1ncc2)cc1c2I NVLXYZOTINRMRQ-UHFFFAOYSA-N 0.000 description 1
- POIRWQKWVBCDKG-UHFFFAOYSA-N COc(nc12)ccc1ncc(F)c2I Chemical compound COc(nc12)ccc1ncc(F)c2I POIRWQKWVBCDKG-UHFFFAOYSA-N 0.000 description 1
- CKJHESVYZJITQQ-UHFFFAOYSA-N COc(nc12)ccc1nccc2I Chemical compound COc(nc12)ccc1nccc2I CKJHESVYZJITQQ-UHFFFAOYSA-N 0.000 description 1
- JRPRUNNJFWRSQJ-UHFFFAOYSA-N COc1ccc(c(F)ccc2I)c2n1 Chemical compound COc1ccc(c(F)ccc2I)c2n1 JRPRUNNJFWRSQJ-UHFFFAOYSA-N 0.000 description 1
- KTLKSJUXFMJBGO-UHFFFAOYSA-N COc1ccc(cccc2I)c2n1 Chemical compound COc1ccc(cccc2I)c2n1 KTLKSJUXFMJBGO-UHFFFAOYSA-N 0.000 description 1
- UVSZTOQVAVLPLY-XYPYZODXSA-N COc1cnc(ccc(F)c2CN[C@H](CC3)CC[C@@H]3N)c2n1 Chemical compound COc1cnc(ccc(F)c2CN[C@H](CC3)CC[C@@H]3N)c2n1 UVSZTOQVAVLPLY-XYPYZODXSA-N 0.000 description 1
- JKZUGQDQSVKMIE-UHFFFAOYSA-N COc1nc(c(I)c(cc2)F)c2cc1 Chemical compound COc1nc(c(I)c(cc2)F)c2cc1 JKZUGQDQSVKMIE-UHFFFAOYSA-N 0.000 description 1
- ARWYAWKWPGRQHX-KNTRFNDTSA-N C[C@@H](c1ccccc1)N[C@@H](CC[C@@H](C1)NOC(c2ccccc2)=O)[C@H]1O Chemical compound C[C@@H](c1ccccc1)N[C@@H](CC[C@@H](C1)NOC(c2ccccc2)=O)[C@H]1O ARWYAWKWPGRQHX-KNTRFNDTSA-N 0.000 description 1
- ARWYAWKWPGRQHX-YGWPLHOASA-N C[C@@H](c1ccccc1)N[C@H](CC[C@H](C1)NOC(c2ccccc2)=O)[C@@H]1O Chemical compound C[C@@H](c1ccccc1)N[C@H](CC[C@H](C1)NOC(c2ccccc2)=O)[C@@H]1O ARWYAWKWPGRQHX-YGWPLHOASA-N 0.000 description 1
- ZRYQANAKIAPMPW-UHFFFAOYSA-N Cc(cc1)c(ccc(OC)c2)c2c1NC Chemical compound Cc(cc1)c(ccc(OC)c2)c2c1NC ZRYQANAKIAPMPW-UHFFFAOYSA-N 0.000 description 1
- FQZCUAASVCIWSL-UHFFFAOYSA-N Nc(cc(c(F)c1)Br)c1F Chemical compound Nc(cc(c(F)c1)Br)c1F FQZCUAASVCIWSL-UHFFFAOYSA-N 0.000 description 1
- NMHHNWXOHNOHBJ-UHFFFAOYSA-N O=C1Nc(nc(CNC2CCCCC2)cn2)c2OC1 Chemical compound O=C1Nc(nc(CNC2CCCCC2)cn2)c2OC1 NMHHNWXOHNOHBJ-UHFFFAOYSA-N 0.000 description 1
- BZTYGYDSIJOIJQ-UHFFFAOYSA-N O=C1Nc(nc(cn2)Cl)c2OC1 Chemical compound O=C1Nc(nc(cn2)Cl)c2OC1 BZTYGYDSIJOIJQ-UHFFFAOYSA-N 0.000 description 1
- AXVPMSMOPJYOCS-UHFFFAOYSA-N O=Cc(nc1N2)cnc1OCC2=O Chemical compound O=Cc(nc1N2)cnc1OCC2=O AXVPMSMOPJYOCS-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
- C07D498/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5383—1,4-Oxazines, e.g. morpholine ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
- A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dispersion Chemistry (AREA)
- Otolaryngology (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicinal Preparation (AREA)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2019200226A AU2019200226B2 (en) | 2015-08-16 | 2019-01-14 | Antibacterial agents comprising a pyrazino[2,3-b][1,4]oxazin-3-one or a related ring system |
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201562205732P | 2015-08-16 | 2015-08-16 | |
| US62/205,732 | 2015-08-16 | ||
| US201662308928P | 2016-03-16 | 2016-03-16 | |
| US62/308,928 | 2016-03-16 | ||
| PCT/IB2016/054890 WO2017029602A2 (en) | 2015-08-16 | 2016-08-15 | Compounds for use in antibacterial applications |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019200226A Division AU2019200226B2 (en) | 2015-08-16 | 2019-01-14 | Antibacterial agents comprising a pyrazino[2,3-b][1,4]oxazin-3-one or a related ring system |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| AU2016307969A1 AU2016307969A1 (en) | 2018-03-08 |
| AU2016307969B2 AU2016307969B2 (en) | 2019-02-14 |
| AU2016307969C1 true AU2016307969C1 (en) | 2019-09-05 |
Family
ID=57218948
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2016307969A Ceased AU2016307969C1 (en) | 2015-08-16 | 2016-08-15 | Antibacterial agents comprising a pyrazino[2,3-b][1,4]oxazin-3-one or a related ring system |
| AU2019200226A Ceased AU2019200226B2 (en) | 2015-08-16 | 2019-01-14 | Antibacterial agents comprising a pyrazino[2,3-b][1,4]oxazin-3-one or a related ring system |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AU2019200226A Ceased AU2019200226B2 (en) | 2015-08-16 | 2019-01-14 | Antibacterial agents comprising a pyrazino[2,3-b][1,4]oxazin-3-one or a related ring system |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US10364254B2 (enExample) |
| EP (1) | EP3334739A2 (enExample) |
| JP (1) | JP6757402B2 (enExample) |
| KR (1) | KR20180038046A (enExample) |
| CN (1) | CN108137616B (enExample) |
| AU (2) | AU2016307969C1 (enExample) |
| CA (1) | CA2995715A1 (enExample) |
| CL (1) | CL2018000403A1 (enExample) |
| CO (1) | CO2018002204A2 (enExample) |
| CR (1) | CR20180111A (enExample) |
| DO (1) | DOP2018000049A (enExample) |
| EA (1) | EA033314B1 (enExample) |
| HK (1) | HK1248680A1 (enExample) |
| IL (1) | IL257265B (enExample) |
| MA (1) | MA42621A (enExample) |
| MX (1) | MX2018002033A (enExample) |
| PE (1) | PE20181143A1 (enExample) |
| PH (1) | PH12018500358A1 (enExample) |
| TW (1) | TW201722965A (enExample) |
| UY (1) | UY36851A (enExample) |
| WO (1) | WO2017029602A2 (enExample) |
| ZA (1) | ZA201800722B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY36851A (es) * | 2015-08-16 | 2017-03-31 | Glaxosmithkline Ip Dev Ltd | Compuestos para uso en aplicaciones antibacterianas |
| WO2019180634A1 (en) | 2018-03-23 | 2019-09-26 | Glaxosmithkline Intellectual Property Development Limited | Synthesis of oxazinone-containing bicyclic aromatic and heteroaromatic aldehydes |
| TW202116782A (zh) | 2019-07-16 | 2021-05-01 | 瑞士商愛杜西亞製藥有限公司 | 喹啉酮衍生物 |
| CN111269247B (zh) * | 2020-03-04 | 2020-11-24 | 河南科技大学第一附属医院 | 具有抑制大肠杆菌作用的噻嗪酮药物分子的制备方法 |
| KR20240161147A (ko) | 2022-03-14 | 2024-11-12 | 슬랩 파마슈티컬스 엘엘씨 | 다중 사이클릭 화합물 |
| AR134764A1 (es) | 2023-12-21 | 2026-04-01 | Glaxosmithkline Intellectual Property No 4 Ltd | Compuestos químicos y usos de los mismos |
Citations (14)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4632671B1 (enExample) * | 1969-10-13 | 1971-09-23 | Eisai Co Ltd | |
| WO2004002490A2 (en) * | 2002-06-26 | 2004-01-08 | Glaxo Group Limited | Piperidine compounds as antibacterials |
| WO2004002992A1 (en) * | 2002-06-26 | 2004-01-08 | Glaxo Group Limited | Compounds |
| WO2004087145A2 (en) * | 2003-03-27 | 2004-10-14 | Glaxo Group Limited | Antibacterial agents |
| WO2006081264A1 (en) * | 2005-01-25 | 2006-08-03 | Glaxo Group Limited | Antibacterial agents |
| WO2007093963A1 (en) * | 2006-02-15 | 2007-08-23 | Actelion Pharmaceuticals Ltd | Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives |
| WO2008078305A2 (en) * | 2006-12-22 | 2008-07-03 | Actelion Pharmaceuticals Ltd | 4-(1-amino-ethyl)-cyclohexylamine derivatives |
| WO2008128961A1 (en) * | 2007-04-20 | 2008-10-30 | Glaxo Group Limited | Compounds |
| US20090131444A1 (en) * | 2005-05-24 | 2009-05-21 | Astrazeneca Ab | Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity |
| US20090270374A1 (en) * | 2006-07-20 | 2009-10-29 | Llius Ballell | Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones |
| WO2010046388A1 (en) * | 2008-10-23 | 2010-04-29 | Glaxo Group Limited | Substituted (aza) -1-methyl-1h-quinolin-2-ones as antibacterials |
| WO2010055348A1 (en) * | 2008-11-14 | 2010-05-20 | Astrazeneca Ab | [4- (1-amino-ethyl) -cyclohexyl] -methyl-amines as antibacterials |
| WO2011148962A1 (ja) * | 2010-05-25 | 2011-12-01 | 大正製薬株式会社 | 新規な複素環化合物又はその塩 |
| US20140243302A1 (en) * | 2011-06-27 | 2014-08-28 | Merck Sharp & Dohme Corporation | Bridged bicyclic compounds for the treatment of bacterial infections |
Family Cites Families (74)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| CY1308A (en) | 1979-12-06 | 1985-12-06 | Glaxo Group Ltd | Device for dispensing medicaments |
| ATE23272T1 (de) | 1981-07-08 | 1986-11-15 | Draco Ab | Pulverinhalator. |
| US4778054A (en) | 1982-10-08 | 1988-10-18 | Glaxo Group Limited | Pack for administering medicaments to patients |
| GB2169265B (en) | 1982-10-08 | 1987-08-12 | Glaxo Group Ltd | Pack for medicament |
| NL192564C (nl) | 1982-10-08 | 1997-10-03 | Glaxo Group Ltd | Inrichting voor het toedienen van medicamenten aan patiënten. |
| EP0211595B1 (en) | 1985-07-30 | 1991-11-13 | Glaxo Group Limited | Devices for administering medicaments to patients |
| JPH0733379B2 (ja) * | 1986-06-27 | 1995-04-12 | エーザイ株式会社 | 光学活性α−トコフエロ−ルの製造方法 |
| HU213221B (en) | 1990-03-02 | 1997-03-28 | Glaxo Group Ltd | Inhalation device and medicine packet for device |
| GB9004781D0 (en) | 1990-03-02 | 1990-04-25 | Glaxo Group Ltd | Device |
| US6536427B2 (en) | 1990-03-02 | 2003-03-25 | Glaxo Group Limited | Inhalation device |
| IL115849A0 (en) | 1994-11-03 | 1996-01-31 | Merz & Co Gmbh & Co | Tangential filtration preparation of liposomal drugs and liposome product thereof |
| GB9700226D0 (en) | 1997-01-08 | 1997-02-26 | Glaxo Group Ltd | Inhalation device |
| US5827533A (en) | 1997-02-06 | 1998-10-27 | Duke University | Liposomes containing active agents aggregated with lipid surfactants |
| FR2798656B1 (fr) | 1999-09-17 | 2004-12-17 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leur preparation et les compositions qui les contiennent |
| PL364808A1 (en) | 2000-07-21 | 2004-12-13 | Ljudmila Petrovna Maljuk | Plate for a stand-up meal |
| NZ523749A (en) | 2000-07-26 | 2005-03-24 | Smithkline Beecham P | Aminopiperidine quinolines and their azaisosteric analogues with antibacterial activity |
| FR2816618B1 (fr) | 2000-11-15 | 2002-12-27 | Aventis Pharma Sa | Derives heterocyclylalcoyl piperidine, leur preparation et les compositions qui les contiennent |
| GB0031088D0 (en) | 2000-12-20 | 2001-01-31 | Smithkline Beecham Plc | Medicaments |
| EP1345903A1 (en) | 2000-12-21 | 2003-09-24 | Ciba SC Holding AG | Crystalline forms of cerivastatin sodium |
| GB0101577D0 (en) | 2001-01-22 | 2001-03-07 | Smithkline Beecham Plc | Compounds |
| GB0112834D0 (en) * | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| GB0112836D0 (en) | 2001-05-25 | 2001-07-18 | Smithkline Beecham Plc | Medicaments |
| GB0118238D0 (en) | 2001-07-26 | 2001-09-19 | Smithkline Beecham Plc | Medicaments |
| GB0201677D0 (en) | 2002-01-25 | 2002-03-13 | Glaxo Group Ltd | Medicament dispenser |
| WO2003064431A2 (en) | 2002-01-29 | 2003-08-07 | Glaxo Group Limited | Aminopiperidine compounds, process for their preparation, and pharmaceutical compositions containing them |
| US7312212B2 (en) | 2002-01-29 | 2007-12-25 | Glaxo Group Limited | Aminopiperidine derivatives |
| US20060014786A1 (en) * | 2002-05-17 | 2006-01-19 | Rajeev Raut | Opthalmic pharmaceutical compositions and methods for treating ocular inflammation |
| CN100427487C (zh) | 2002-06-27 | 2008-10-22 | 弗·哈夫曼·拉罗切有限公司 | 嘌呤衍生物的合成 |
| GB0217294D0 (en) | 2002-07-25 | 2002-09-04 | Glaxo Group Ltd | Medicaments |
| FR2844268B1 (fr) | 2002-09-11 | 2004-10-22 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leurs procedes et intermediaires de preparation et les compositions qui les contiennent |
| FR2844270B1 (fr) | 2002-09-11 | 2006-05-19 | Aventis Pharma Sa | Derives de la quinolyl propyl piperidine, leur procede et intermediaires de preparation et les compositions qui les contiennent |
| EP1551829B1 (de) | 2002-10-10 | 2010-04-07 | Morphochem Aktiengesellschaft Für Kombinatorische Chemie | Neue verbindungen mit antibakterieller aktivität |
| AU2003291227A1 (en) | 2002-11-05 | 2004-06-07 | Smithkline Beecham Corporation | Antibacterial agents |
| ES2340484T3 (es) | 2002-11-05 | 2010-06-04 | Glaxo Group Limited | Agentes antibacterianos. |
| AR042486A1 (es) | 2002-12-18 | 2005-06-22 | Glaxo Group Ltd | Compuesto de quinolina y naftiridina halosustituido en la posicion 3, procedimiento para preparar el compuesto, composicion farmaceutica que lo comprende y su uso para preparar dicha composicion . |
| FR2852954B1 (fr) | 2003-03-28 | 2006-07-14 | Aventis Pharma Sa | Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent |
| DE10316081A1 (de) | 2003-04-08 | 2004-10-21 | Morphochem AG Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
| FR2858619B1 (fr) | 2003-08-08 | 2006-12-22 | Aventis Pharma Sa | Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent |
| US9214590B2 (en) | 2003-12-19 | 2015-12-15 | The University Of North Carolina At Chapel Hill | High fidelity nano-structures and arrays for photovoltaics and methods of making the same |
| US8263129B2 (en) | 2003-12-19 | 2012-09-11 | The University Of North Carolina At Chapel Hill | Methods for fabricating isolated micro-and nano-structures using soft or imprint lithography |
| FR2867472B1 (fr) | 2004-03-12 | 2008-07-18 | Aventis Pharma Sa | Derives de quinoleines-4-substituees, leurs procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent |
| JP2008502689A (ja) | 2004-06-15 | 2008-01-31 | グラクソ グループ リミテッド | 抗菌剤 |
| FR2872164B1 (fr) | 2004-06-29 | 2006-11-17 | Aventis Pharma Sa | Derives de quinoleines-4-substituees, leur procede et intermediaires de preparation et les compositions pharmaceutiques qui les contiennent |
| EP1773831A1 (en) | 2004-07-08 | 2007-04-18 | Glaxo Group Limited | Antibacterial agents |
| EP1773847A2 (en) * | 2004-07-09 | 2007-04-18 | Glaxo Group Limited | Antibacterial agents |
| JP2008506695A (ja) | 2004-07-13 | 2008-03-06 | グラクソ グループ リミテッド | 抗細菌剤 |
| JP2008507543A (ja) | 2004-07-22 | 2008-03-13 | グラクソ グループ リミテッド | 抗細菌剤 |
| JP2008508359A (ja) | 2004-08-02 | 2008-03-21 | グラクソ グループ リミテッド | 抗菌剤 |
| JP2008509222A (ja) | 2004-08-09 | 2008-03-27 | グラクソ グループ リミテッド | 抗菌剤 |
| DE102004041163A1 (de) * | 2004-08-25 | 2006-03-02 | Morphochem Aktiengesellschaft für kombinatorische Chemie | Neue Verbindungen mit antibakterieller Aktivität |
| JP4887297B2 (ja) | 2004-09-24 | 2012-02-29 | アクテリオン ファーマシューティカルズ リミテッド | 新規二環式抗生物質 |
| DE602005021133D1 (de) | 2004-10-05 | 2010-06-17 | Actelion Pharmaceuticals Ltd | Neue piperidin-antibiotika |
| WO2006046552A1 (ja) | 2004-10-27 | 2006-05-04 | Toyama Chemical Co., Ltd. | 新規な含窒素複素環化合物およびその塩 |
| MY150958A (en) | 2005-06-16 | 2014-03-31 | Astrazeneca Ab | Compounds for the treatment of multi-drug resistant bacterial infections |
| WO2006137485A1 (ja) | 2005-06-24 | 2006-12-28 | Toyama Chemical Co., Ltd. | 新規な含窒素複素環化合物およびその塩 |
| GB0515584D0 (en) | 2005-07-28 | 2005-09-07 | Glaxo Group Ltd | Medicament dispenser |
| EP1922364A4 (en) | 2005-08-09 | 2010-04-21 | Univ North Carolina | METHOD AND MATERIALS FOR PRODUCING MICROFLUIDIC DEVICES |
| AR058289A1 (es) | 2005-12-12 | 2008-01-30 | Glaxo Group Ltd | Colector para ser usado en dispensador de medicamento |
| DOP2006000268A (es) | 2005-12-22 | 2007-07-31 | Pfizer Prod Inc | Agentes antibacterianos |
| WO2007081876A2 (en) | 2006-01-04 | 2007-07-19 | Liquidia Technologies, Inc. | Nanostructured surfaces for biomedical/biomaterial applications and processes thereof |
| MX2008014908A (es) | 2006-05-26 | 2009-05-13 | Toyama Chemical Co Ltd | Compuesto heterociclico nuevo o sal del mismo e intermedio del mismo. |
| US8465775B2 (en) | 2006-07-27 | 2013-06-18 | The University Of North Carolina At Chapel Hill | Nanoparticle fabrication methods, systems, and materials for fabricating artificial red blood cells |
| US8128393B2 (en) | 2006-12-04 | 2012-03-06 | Liquidia Technologies, Inc. | Methods and materials for fabricating laminate nanomolds and nanoparticles therefrom |
| WO2009024342A2 (en) * | 2007-08-23 | 2009-02-26 | Syngenta Participations Ag | Novel microbiocides |
| CN101896337B (zh) | 2007-10-12 | 2013-10-30 | 流体科技公司 | 用于生产颗粒和图案化膜的系统和方法 |
| JP5620636B2 (ja) | 2007-11-26 | 2014-11-05 | 富山化学工業株式会社 | 新規な複素環化合物またはその塩を含有する抗菌剤 |
| KR101294962B1 (ko) * | 2008-10-07 | 2013-08-12 | 액테리온 파마슈티칼 리미티드 | 트리사이클 옥사졸리디논 항생제 화합물 |
| KR101880582B1 (ko) | 2008-12-05 | 2018-07-20 | 리퀴디아 테크놀로지스 인코포레이티드 | 패턴 재료 제조 방법 |
| CN102232078B (zh) * | 2008-12-12 | 2014-07-16 | 埃科特莱茵药品有限公司 | 5-氨基-2-(1-羟基-乙基)-四氢吡喃衍生物 |
| WO2011008737A2 (en) | 2009-07-13 | 2011-01-20 | The University Of North Carolina At Chapel Hill | Engineered aerosol particles, and associated methods |
| EP2785721A1 (en) * | 2011-11-30 | 2014-10-08 | Actelion Pharmaceuticals Ltd. | 3,7-disubstituted octahydro-2h-pyrido[4,3-e][1,3]oxazin-2-one antibiotics |
| EA029361B1 (ru) | 2013-04-16 | 2018-03-30 | Идорсиа Фармасьютиклз Лтд | Антибактериальные биароматические производные |
| UY36851A (es) * | 2015-08-16 | 2017-03-31 | Glaxosmithkline Ip Dev Ltd | Compuestos para uso en aplicaciones antibacterianas |
-
2016
- 2016-08-12 UY UY0001036851A patent/UY36851A/es not_active Application Discontinuation
- 2016-08-12 TW TW105125824A patent/TW201722965A/zh unknown
- 2016-08-15 EP EP16788799.1A patent/EP3334739A2/en not_active Withdrawn
- 2016-08-15 JP JP2018507672A patent/JP6757402B2/ja not_active Expired - Fee Related
- 2016-08-15 CA CA2995715A patent/CA2995715A1/en not_active Abandoned
- 2016-08-15 HK HK18108126.0A patent/HK1248680A1/zh unknown
- 2016-08-15 MA MA042621A patent/MA42621A/fr unknown
- 2016-08-15 US US15/752,639 patent/US10364254B2/en not_active Expired - Fee Related
- 2016-08-15 EA EA201890412A patent/EA033314B1/ru not_active IP Right Cessation
- 2016-08-15 WO PCT/IB2016/054890 patent/WO2017029602A2/en not_active Ceased
- 2016-08-15 CN CN201680056596.4A patent/CN108137616B/zh not_active Expired - Fee Related
- 2016-08-15 CR CR20180111A patent/CR20180111A/es unknown
- 2016-08-15 KR KR1020187007548A patent/KR20180038046A/ko not_active Withdrawn
- 2016-08-15 MX MX2018002033A patent/MX2018002033A/es unknown
- 2016-08-15 PE PE2018000236A patent/PE20181143A1/es unknown
- 2016-08-15 AU AU2016307969A patent/AU2016307969C1/en not_active Ceased
-
2018
- 2018-01-31 IL IL257265A patent/IL257265B/en active IP Right Grant
- 2018-02-02 ZA ZA2018/00722A patent/ZA201800722B/en unknown
- 2018-02-14 CL CL2018000403A patent/CL2018000403A1/es unknown
- 2018-02-15 PH PH12018500358A patent/PH12018500358A1/en unknown
- 2018-02-16 DO DO2018000049A patent/DOP2018000049A/es unknown
- 2018-02-27 CO CONC2018/0002204A patent/CO2018002204A2/es unknown
-
2019
- 2019-01-14 AU AU2019200226A patent/AU2019200226B2/en not_active Ceased
- 2019-05-17 US US16/415,319 patent/US10683307B2/en not_active Expired - Fee Related
Patent Citations (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS4632671B1 (enExample) * | 1969-10-13 | 1971-09-23 | Eisai Co Ltd | |
| WO2004002490A2 (en) * | 2002-06-26 | 2004-01-08 | Glaxo Group Limited | Piperidine compounds as antibacterials |
| WO2004002992A1 (en) * | 2002-06-26 | 2004-01-08 | Glaxo Group Limited | Compounds |
| WO2004087145A2 (en) * | 2003-03-27 | 2004-10-14 | Glaxo Group Limited | Antibacterial agents |
| WO2006081264A1 (en) * | 2005-01-25 | 2006-08-03 | Glaxo Group Limited | Antibacterial agents |
| US20090131444A1 (en) * | 2005-05-24 | 2009-05-21 | Astrazeneca Ab | Aminopiperidine Quinolines and Their Azaisosteric Analogues with Antibacterial Activity |
| WO2007093963A1 (en) * | 2006-02-15 | 2007-08-23 | Actelion Pharmaceuticals Ltd | Ethanol or 1,2-ethanediol cyclohexyl antibiotic derivatives |
| US20090270374A1 (en) * | 2006-07-20 | 2009-10-29 | Llius Ballell | Derivatives and analogs of n-ethylquinolones and n-ethylazaquinolones |
| WO2008078305A2 (en) * | 2006-12-22 | 2008-07-03 | Actelion Pharmaceuticals Ltd | 4-(1-amino-ethyl)-cyclohexylamine derivatives |
| US20100029623A1 (en) * | 2006-12-22 | 2010-02-04 | Actelion Pharmaceuticals Ltd. | 4-(1-amino-ethyl)-cyclohexylamine derivatives |
| WO2008128961A1 (en) * | 2007-04-20 | 2008-10-30 | Glaxo Group Limited | Compounds |
| WO2010046388A1 (en) * | 2008-10-23 | 2010-04-29 | Glaxo Group Limited | Substituted (aza) -1-methyl-1h-quinolin-2-ones as antibacterials |
| WO2010055348A1 (en) * | 2008-11-14 | 2010-05-20 | Astrazeneca Ab | [4- (1-amino-ethyl) -cyclohexyl] -methyl-amines as antibacterials |
| WO2011148962A1 (ja) * | 2010-05-25 | 2011-12-01 | 大正製薬株式会社 | 新規な複素環化合物又はその塩 |
| US20140243302A1 (en) * | 2011-06-27 | 2014-08-28 | Merck Sharp & Dohme Corporation | Bridged bicyclic compounds for the treatment of bacterial infections |
Non-Patent Citations (1)
| Title |
|---|
| RECK FOLKERT ET AL, "Optimization of physicochemical properties and safety profile of novel bacterial topoisomerase type II inhibitors (NBTIs)", BIOORGANIC & MEDICINAL CHEMISTRY, PERGAMON, (2014-08-04), vol. 22, no. 19, pages 5392 - 5409 * |
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2019200226B2 (en) | Antibacterial agents comprising a pyrazino[2,3-b][1,4]oxazin-3-one or a related ring system | |
| CN115087440A (zh) | Trpml调节剂 | |
| AU2022200478B2 (en) | Inhibitors of KEAP1-Nrf2 protein-protein interaction | |
| UA128751C2 (uk) | Інгібітори rip1k | |
| CN114728958A (zh) | Rip1抑制性化合物和制备与使用其的方法 | |
| JP2023134444A (ja) | ピペリジニル－３－（アリールオキシ）プロパンアミド及びプロパノエート | |
| JP2010521528A (ja) | Ｃｎｓ活性化合物としてのインドリジン及びそのアザ類似誘導体 | |
| CA2876370A1 (en) | Compounds and methods for treating hiv | |
| CA2959747C (en) | Compounds as crth2 antagonist and uses thereof | |
| WO2016015593A1 (en) | FACTOR XIa INHIBITORS | |
| AU2016209623B2 (en) | Factor XIa inhibitors | |
| CN103396396B (zh) | 胺基烷酰克林沙星及其应用 | |
| WO2023109909A1 (zh) | 一种芳杂环类化合物及其制备方法和用途 | |
| CN115636833A (zh) | 作为ATM激酶选择性调节剂的取代的咪唑并[4,5-c]噌啉-2-酮化合物及其用途 | |
| JP2008528604A (ja) | 抗菌剤 | |
| JP6526064B2 (ja) | ピリドピリミジンジオン誘導体 | |
| WO2017093938A1 (en) | Tetrahydroisoquinoline derivatives | |
| CN103450220B (zh) | 一种硝基咪唑类化合物及其在药学中的用途 | |
| HK40112157A (zh) | Enpp1抑制剂的药物用途 | |
| JPH04159283A (ja) | リファマイシン誘導体およびその製造方法 | |
| WO2025214463A1 (zh) | 含有三并环结构的化合物 | |
| TW202535889A (zh) | 泛-kras抑制劑及其在醫藥上的應用 | |
| WO2025230875A1 (en) | Compounds and their use for treatment of hemoglobinopathies | |
| WO2022234287A1 (en) | Imidazopyridazine derivatives useful as trk inhibitors | |
| EA044922B1 (ru) | ИНГИБИТОРЫ БЕЛОК-БЕЛКОВОГО ВЗАИМОДЕЙСТВИЯ KEAP1-Nrf2 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| DA2 | Applications for amendment section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 MAY 2019 |
|
| DA3 | Amendments made section 104 |
Free format text: THE NATURE OF THE AMENDMENT IS AS SHOWN IN THE STATEMENT(S) FILED 22 MAY 2019 |
|
| FGA | Letters patent sealed or granted (standard patent) | ||
| MK14 | Patent ceased section 143(a) (annual fees not paid) or expired |